As President Joe Biden’s pandemic relief package steams through Congress, Democrats have hitched a ride for a top health care priority: strengthening the Affordable Care Act with some of the most significant changes to insurance affordability in more than a decade.
Late last month Congress passed a nearly 5,600-page legislative package that included $900 billion for urgent pandemic relief, a ban on surprise medical bills and other non-COVID health care issues.
Federal officials offering emergency funding to hospitals, clinics and doctors’ practices have included this stipulation: They cannot foist surprise medical bills on COVID-19 patients.
House Democrats are poised to pass sweeping legislation to lower drug prices using strategies President Donald Trump has endorsed. A Trump aide urged the Republican-controlled Senate to vote on a different package curbing drug prices that was drafted by a senior Republican.
When Washington returned from its winter holiday break in January, it seemed everyone was talking about lowering drug prices.
Three of the lawmakers who will lead the House next year as Congress focuses on skyrocketing drug costs are among the biggest recipients of campaign contributions from the pharmaceutical industry, a new KHN analysis shows.
For the first time since passing the Affordable Care Act, Democrats will soon control the House of Representatives and its powerful health committees. But Republicans’ tightened grip on the Senate means those hoping for another round of dramatic, progressive reforms may be disappointed.
There are many lawmakers who made their names in health care, seeking to usher through historic changes to a broken system.
John McCain was not one of them.
With the country on course to enshrine the rights of transgender Americans, Wren Vetens introduced herself as a woman for the first time in January 2016, at the annual meeting of the American Astronomical Society.